Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (121-130 of 324) with videos related to

Pageof 33
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
Clinical and Vaccine Immunology : CVI|October 20, 2006
Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samplesWayne B Dyer, Sarah L Pett, John S Sullivan, et al.
International Journal of STD & AIDS|July 30, 2008
Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited settingSomsamorn Mangclaviraj, Stephen J Kerr, Surasith Chaithongwongwatthana, et al.
The Journal of Infectious Diseases|October 31, 2009
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional studyAlexandra Calmy, Christoph A Fux, Richard Norris, et al.
Journal of Medical Virology|October 14, 2003
Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progressionElizabeth Keoshkerian, Lesley J Ashton, Danielle G Smith, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophyDianne L Carey, David Baker, Gary D Rogers, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2006
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicityMark A Boyd, Umaporn Siangphoe, Kiat Ruxrungtham, et al.
Journal of the International AIDS Society|February 25, 2011
Trends in detectable viral load by calendar year in the Australian HIV observational databaseMatthew G Law, Ian Woolley, David J Templeton, et al.
Antiviral Therapy|March 9, 2005
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophyJason C Kovacic, Allison Martin, Dianne Carey, et al.
AIDS (London, England)|January 26, 2005
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited settingChris Duncombe, Stephen J Kerr, Kiat Ruxrungtham, et al.
Pageof 33

Showing results (121-130 of 324) with videos related to

Sort By:
Pageof 33
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
Clinical and Vaccine Immunology : CVI|October 20, 2006
Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samplesWayne B Dyer, Sarah L Pett, John S Sullivan, et al.
International Journal of STD & AIDS|July 30, 2008
Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited settingSomsamorn Mangclaviraj, Stephen J Kerr, Surasith Chaithongwongwatthana, et al.
The Journal of Infectious Diseases|October 31, 2009
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional studyAlexandra Calmy, Christoph A Fux, Richard Norris, et al.
Journal of Medical Virology|October 14, 2003
Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progressionElizabeth Keoshkerian, Lesley J Ashton, Danielle G Smith, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophyDianne L Carey, David Baker, Gary D Rogers, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2006
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicityMark A Boyd, Umaporn Siangphoe, Kiat Ruxrungtham, et al.
Journal of the International AIDS Society|February 25, 2011
Trends in detectable viral load by calendar year in the Australian HIV observational databaseMatthew G Law, Ian Woolley, David J Templeton, et al.
Antiviral Therapy|March 9, 2005
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophyJason C Kovacic, Allison Martin, Dianne Carey, et al.
AIDS (London, England)|January 26, 2005
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited settingChris Duncombe, Stephen J Kerr, Kiat Ruxrungtham, et al.
Pageof 33